Clinical Trial

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2024-09-03; most recent amendment 2026-07-14.
Status change: Not Yet Recruiting → Recruiting 2024-11-08
Trial Details
NCT Number NCT06585449
Lead Sponsor Alnylam Pharmaceuticals
Conditions Huntington's Disease
Enrollment 66 participants
Start Date 2024-10-14
Primary Completion 2028-07-05 (estimated)
Study Completion 2028-07-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12